Torben Plesner

15.2k total citations · 2 hit papers
169 papers, 5.6k citations indexed

About

Torben Plesner is a scholar working on Hematology, Oncology and Molecular Biology. According to data from OpenAlex, Torben Plesner has authored 169 papers receiving a total of 5.6k indexed citations (citations by other indexed papers that have themselves been cited), including 110 papers in Hematology, 74 papers in Oncology and 53 papers in Molecular Biology. Recurrent topics in Torben Plesner's work include Multiple Myeloma Research and Treatments (93 papers), Chronic Lymphocytic Leukemia Research (31 papers) and Peptidase Inhibition and Analysis (31 papers). Torben Plesner is often cited by papers focused on Multiple Myeloma Research and Treatments (93 papers), Chronic Lymphocytic Leukemia Research (31 papers) and Peptidase Inhibition and Analysis (31 papers). Torben Plesner collaborates with scholars based in Denmark, United States and Netherlands. Torben Plesner's co-authors include Henk M. Lokhorst, Niels W.C.J. van de Donk, Jean‐Marie Delaissé, Tahamtan Ahmadi, A. Kate Sasser, Jakub Krejcik, Michael Ploug, Thomas Levin Andersen, Paul G. Richardson and Keld Danø and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Torben Plesner

163 papers receiving 5.4k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Daratumumab depletes CD38+ immune regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma

2016 649 citations Jakub Krejcik, Inger S. Nijhof et al. Blood profile →
Clinical efficacy of daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma

2016 303 citations Saad Z. Usmani, Brendan M. Weiss et al. Blood profile →

Peers

Countries citing papers authored by Torben Plesner

Since Specialization

Citations

This map shows the geographic impact of Torben Plesner's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Torben Plesner with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Torben Plesner more than expected).

Fields of papers citing papers by Torben Plesner

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Torben Plesner. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Torben Plesner. The network helps show where Torben Plesner may publish in the future.

Co-authorship network of co-authors of Torben Plesner

This figure shows the co-authorship network connecting the top 25 collaborators of Torben Plesner. A scholar is included among the top collaborators of Torben Plesner based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Torben Plesner. Torben Plesner is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Clinical efficacy of daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma 2024 ·Carolina Digital Repository (University of North Carolina at Chapel Hill) ·Andrew Belch, Torben Plesner, Paul G. Richardson, Jianping Wang, Huaibao Feng, Brendan M. Weiss, Amy Axel, Imran Khan, Hareth Nahi, (unknown), Ajai Chari, Nizar J. Bahlis, Henk M. Lokhorst, A. Kate Sasser, Saad Z. Usmani, Sagar Lonial, Clarissa Uhlar, Tahamtan Ahmadi	0
2	Phase I Study of Safety and Pharmacokinetics of RO7297089, an Anti-BCMA/CD16a Bispecific Antibody, in Patients with Relapsed, Refractory Multiple Myeloma 2023 ·SHILAP Revista de lepidopterología ·Torben Plesner, Simon J. Harrison, Hang Quach, Cindy Lee, Adam Bryant, Annette Juul Vangsted, Jane Estell, Michel Delforge, Fritz Offner, Patrick J. Twomey, Voleak Choeurng, Junyi Li, Robert L. Hendricks, Shannon M. Ruppert, Teiko Sumiyoshi, Karen K. Miller, Eunpi Cho, Fredrik Schjesvold	16
3	High Expression of the Costimulatory Checkpoint Factor DNAM-1 by CD4+ T-Cells from Multiple Myeloma Patients Refractory to Daratumumab-Containing Regimens 2022 ·SHILAP Revista de lepidopterología ·(unknown), Line Nederby, Thomas Lund, Torben Plesner	1
4	Clinically‐suspected cast nephropathy: A retrospective, national, real‐world study 2020 ·American Journal of Hematology ·(unknown), Jonathan Thorsen, (unknown), Charlotte T. Hansen, (unknown), (unknown), (unknown), (unknown), Mikael Frederiksen, (unknown), Ulf Christian Frølund, (unknown), Torben Plesner, Annette Juul Vangsted	10
5	Monocytes and Granulocytes Reduce CD38 Expression Levels on Myeloma Cells in Patients Treated with Daratumumab 2017 ·Clinical Cancer Research ·Jakub Krejcik, (unknown), Inger S. Nijhof, Berris van Kessel, Jeroen F. van Velzen, Andries C. Bloem, Marloes E.C. Broekmans, Sonja Zweegman, Johan van Meerloo, René J.P. Musters, Pino J. Poddighe, Richard W.J. Groen, Christopher Chiu, Torben Plesner, Henk M. Lokhorst, A. Kate Sasser, Tuna Mutis, Niels W.C.J. van de Donk	119
6	Practical Considerations for the Use of Daratumumab, a Novel CD38 Monoclonal Antibody, in Myeloma 2016 ·Drugs ·Philippe Moreau, Niels W.C.J. van de Donk, Jesús F. San Miguel, Henk M. Lokhorst, Hareth Nahi, Dina Ben‐Yehuda, Michèle Cavo, Gordon Cook, Michel Delforge, Hermann Einsele, Sonja Zweegman, Heinz Ludwig, Christoph Driessen, Antonio Palumbo, Thierry Façon, Torben Plesner, Meletios Α. Dimopoulos, Pia Sondergeld, Pieter Sonneveld, María‐Victoria Mateos	30
7	Treatment Sequencing Survival Model for Patients with Multiple Myeloma Ineligible for Stem Cell Transplantation (SCT) 2014 ·Value in Health ·Bart Heeg, Michel van Agthoven, (unknown), Johan Liwing, (unknown), Torben Plesner, (unknown), J Aschan, Hermann Einsele, M. Treur, (unknown), Paul G. Richardson, Antonio Palumbo, Hareth Nahi, Pieter Sonneveld	2
8	A phase III randomized trial comparing glucocorticoid monotherapy versus glucocorticoid and rituximab in patients with autoimmune haemolytic anaemia 2013 ·British Journal of Haematology ·Henrik Birgens, Henrik Frederiksen, Hans Carl Hasselbalch, Inge Helleberg Rasmussen, Ove Juul Nielsen, Lars Kjeldsen, Herdis Larsen, Torben Mourits‐Andersen, Torben Plesner, Dorthe Rønnov‐Jessen, Hanne Vestergaard, Tobias Wirenfeldt Klausen, Claudia Schöllkopf	112
9	Rituximab and dexamethasone vs dexamethasone monotherapy in newly diagnosed patients with primary immune thrombocytopenia 2013 ·Blood ·Sif Gudbrandsdottir, Henrik Birgens, Henrik Frederiksen, Bjarne Anker Jensen, Morten Krogh Jensen, Lars Kjeldsen, Tobias Wirenfeldt Klausen, Herdis Larsen, Hans Torben Mourits‐Andersen, Claus Henrik Nielsen, Ove Juul Nielsen, Torben Plesner, (unknown), Inge Helleberg Rasmussen, Dorthe Rønnov‐Jessen, Hans Carl Hasselbalch	125
10	Multiple myeloma: changes in serum C‐terminal telopeptide of collagen type I and bone‐specific alkaline phosphatase can be used in daily practice to detect imminent osteolysis* 2010 ·European Journal Of Haematology ·Thomas Lund, Niels Abildgaard, Thomas Levin Andersen, Jean‐Marie Delaissé, Torben Plesner	22
11	First‐line treatment with bortezomib rapidly stimulates both osteoblast activity and bone matrix deposition in patients with multiple myeloma, and stimulates osteoblast proliferation and differentiation in vitro 2010 ·European Journal Of Haematology ·Thomas Lund, Kent Søe, Niels Abildgaard, Patrick Garnero, Per Trøllund Pedersen, (unknown), Jean‐Marie Delaissé, Torben Plesner	36
12	A phase II clinical trial does not show that high dose simvastatin has beneficial effect on markers of bone turnover in multiple myeloma 2008 ·Hematological Oncology ·Teis Esben Søndergaard, (unknown), (unknown), Kent Søe, Thomas Lund, Brian Østergaard, Patrick Garnero, Jean‐Marie Delaissé, Torben Plesner	45
13	Resveratrol Inhibits Myeloma Cell Growth, Prevents Osteoclast Formation, and Promotes Osteoblast Differentiation 2005 ·Cancer Research ·Patrice Boissy, Thomas Levin Andersen, Basem M. Abdallah, Moustapha Kassem, Torben Plesner, Jean‐Marie Delaissé	167
14	A novel fully human anti-CD20 monoclonal antibody: First clinical results from an ongoing phase I/II trial in patients with follicular non-Hodgkin's lymphoma 2005 ·Annals of Oncology ·Anton Hagenbeek, Torben Plesner, Jan Walewski, Michael Kneba, (unknown), John Radford	3
15	Characterisation of Non-P-Glycoprotein multidrug-resistant Ehrlich ascites tumour cells selected for resistance to mitoxantrone 2000 ·Biochemical Pharmacology ·Dorte Nielsen, Jens Eriksen, Christian Maare, Thomas Litman, E Kjærsgaard, Torben Plesner, Ellen Friche, Torben Skovsgaard	9
16	A soluble form of the glycolipid‐anchored receptor for urokinase‐type plasminogen activator is secreted from peripheral blood leukocytes from patients with paroxysmal nocturnal hemoglobinuria 1992 ·European Journal of Biochemistry ·Michael Ploug, Jens Eriksen, Torben Plesner, Niels Ebbe Hansen, Keld Danø	65
17	T‐Cell Activation. III. Attempts to Activate MHC Class I‐Negative and Class I‐Transfected EL4 T‐Lymphoma Cells by Immobilized Anti‐CD3 Antibody 1990 ·Scandinavian Journal of Immunology ·Mogens H. Claësson, Steen Dissing, Torben Plesner, (unknown), Peter Brams	5
18	Estimation of PI‐bound proteins on blood cells from PNH patients by quantitative flow cytometry 1990 ·British Journal of Haematology ·Torben Plesner, Nicklas Hansen, (unknown)	35
19	T cell activation 1990 ·Cellular Immunology ·Steen Dissing, Carsten Geisler, Bent Rubin, Torben Plesner, Mogens H. Claësson	41
20	Identification of αβ and γδ T Cell Receptor‐Positive Cells 1988 ·Scandinavian Journal of Immunology ·Carsten Geisler, JK Larsen, Torben Plesner	3

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact